Syndax Pharmaceuticals (SNDX) Shares Outstanding (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Shares Outstanding (Entity) of $88.5 million for Q1 2026, up 2.9% year-over-year from $86.0 million in Q1 2025, and up 1.3% quarter-over-quarter from $87.4 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Shares Outstanding (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Shares Outstanding (Entity) history runs 12 years deep, the most recent figure standing at $88.5 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.9% year-over-year to $88.5 million; the TTM figure through Mar 2026 stood at $88.5 million (up 2.9% YoY), while the FY2025 annual figure was $87.4 million, up 2.0% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $88.5 million, up from $87.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $88.5 million in Q1 2026, with the low at $55.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $85.0 million (2024), against an average of $76.1 million.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) climbed 24.47% in 2023, then advanced 1.21% in 2025.
- Syndax Pharmaceuticals' Shares Outstanding (Entity) stood at $68.1 million in 2022, then advanced by 3.32% to $70.4 million in 2023, then rose by 21.78% to $85.7 million in 2024, then increased by 2.0% to $87.4 million in 2025, then grew by 1.3% to $88.5 million in 2026.
- Business Quant data shows SNDX's Shares Outstanding (Entity) at $88.5 million in Q1 2026, $87.4 million in Q4 2025, and $86.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 88.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.99 Mn |
| Mar 31, 2026 | 88.26 Mn |
| Dec 31, 2025 | 86.63 Mn |
| Sep 30, 2025 | 86.62 Mn |
| Jun 30, 2025 | 86.34 Mn |
| Mar 31, 2025 | 86.17 Mn |
| Dec 31, 2024 | 85.62 Mn |
| Sep 30, 2024 | 85.43 Mn |
| Jun 30, 2024 | 85.27 Mn |
| Mar 31, 2024 | 85.21 Mn |
| Dec 31, 2023 | 70.37 Mn |
| Sep 30, 2023 | 69.86 Mn |
| Jun 30, 2023 | 69.64 Mn |
| Mar 31, 2023 | 69.44 Mn |
| Dec 31, 2022 | 60.76 Mn |
| Sep 30, 2022 | 60.67 Mn |
| Jun 30, 2022 | 60.16 Mn |
| Mar 31, 2022 | 58.98 Mn |
| Dec 31, 2021 | 52.07 Mn |
| Sep 30, 2021 | 51.96 Mn |